BrainsWay Ltd. (BWAY)

Market Cap	694.68M +336.3%
Revenue (ttm)	52.23M +27.3%
Net Income	7.58M +159.3%
EPS	0.18 +229.1%
Shares Out	40.03M
PE Ratio	91.71
Forward PE	56.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,573
Open	17.11
Previous Close	16.71
Day's Range	16.79 - 17.26
52-Week Range	4.31 - 17.26
Beta	0.22
Analysts	Strong Buy
Price Target	13.25 (-22.83%)
Earnings Date	May 13, 2026

About BWAY

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves do...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 17, 2019
• Employees: 129
• Stock Exchange: NASDAQ
• Ticker Symbol: BWAY
• Website: https://www.brainsway.com

Financial Performance

In 2025, BrainsWay's revenue was $52.23 million, an increase of 27.33% compared to the previous year's $41.02 million. Earnings were $7.58 million, an increase of 159.33%.

Analyst Summary

According to 2 analysts, the average rating for BWAY stock is "Strong Buy." The 12-month stock price target is $13.25, which is a decrease of -22.83% from the latest price.

Price Target

$13.25

(-22.83% downside)

Analyst Consensus: Strong Buy